NASDAQ:FBLG FibroBiologics Q1 2025 Earnings Report $0.53 -0.01 (-1.80%) Closing price 04:00 PM EasternExtended Trading$0.53 +0.00 (+0.09%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast FibroBiologics EPS ResultsActual EPS-$0.12Consensus EPS -$0.11Beat/MissMissed by -$0.01One Year Ago EPSN/AFibroBiologics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AFibroBiologics Announcement DetailsQuarterQ1 2025Date7/31/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsFibroBiologics' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) FibroBiologics Earnings HeadlinesFibroBiologics' (FBLG) "Buy" Rating Reiterated at HC WainwrightSeptember 15 at 3:07 AM | americanbankingnews.comFibroBiologics publishes opinion editorial on stem cell therapiesSeptember 12, 2025 | msn.comThis Coin Could Explode, and it’s Hiding in Plain Sight!Crypto market dominance: 28% and growing fast Think about it: When one protocol controls nearly 30% of a trillion-dollar market, what happens to its token price when that market explodes? Our #1 Coin Report reveals exactly which protocol this is and why its dominance is just getting started.September 16 at 2:00 AM | Crypto 101 Media (Ad)FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell TherapiesSeptember 12, 2025 | globenewswire.comFibroBiologics announces IND-enabling updates from psoriasis research programSeptember 11, 2025 | msn.comFibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis TreatmentSeptember 11, 2025 | globenewswire.comSee More FibroBiologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email. Email Address About FibroBiologicsFibroBiologics (NASDAQ:FBLG), Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.View FibroBiologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
